Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Linagliptin (Primary) ; Insulin
- Indications COVID 2019 infections; Hyperglycaemia; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Covid19DPP4i
- 19 Mar 2021 Status changed from recruiting to completed.
- 10 Sep 2020 New trial record